{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:53:12Z","timestamp":1780415592458,"version":"3.54.1"},"reference-count":48,"publisher":"Cambridge University Press (CUP)","license":[{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"unspecified","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["Epidemiol. Infect."],"published-print":{"date-parts":[[2025]]},"abstract":"<jats:title>Abstract<\/jats:title>\n\t  <jats:p>Current standard microbiological techniques are generally very time consuming, usually requiring 24\u201372\u00a0h to establish a diagnosis. Consequentially, contemporary clinical practices implement broad-spectrum antibiotic administration prior to pathogen detection, prompting the emergence of extremely dangerous antibiotic-resistant bacteria. Additionally, lengthy test-to-result turnover times can greatly exacerbate the rate of disease spread. Rapid point-of-care (POC) diagnostics has quickly gained importance since the SARS-CoV-2 pandemic; accordingly, we have developed a rapid four-channel POC plasmonic quantitative polymerase chain reaction (qPCR) machine (Kimera P-IV) to respond to the deficiencies in infection control. Utilizing gold nanorods (GNRs) as nano-heaters and integrating vertical cavity surface emitting lasers (VCSEL) to replace traditional Peltier blocks, the Kimera P-IV has also incorporated quantitative real-time fluorescent monitoring. Using <jats:italic>Chlamydia trachomatis<\/jats:italic> genetic material to evaluate the rapid thermocycling performance of the platform, we have generated positive amplicons in less than 13\u00a0min; however, to achieve these results, several biological reagent considerations needed to be taken into account, specifically primer design. The device can achieve a limit of detection (LoD) of &lt;10<jats:sup>1<\/jats:sup> DNA copies, a PCR efficiency of 88.3%, and can differentiate positive from negative results with 100% accuracy. Moreover, it can also analyze <jats:italic>C. trachomatis<\/jats:italic> DNA spiked urine samples via a simple dilution, suggesting that a separate nucleic acid step may not be needed for diagnosing infections. In conclusion, the operation of the Kimera P-IV prototype places it in a unique position of POC devices to revolutionize infectious disease diagnosis.<\/jats:p>","DOI":"10.1017\/s0950268825000081","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T03:37:42Z","timestamp":1738208262000},"update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":3,"title":["Performance and functional assessment of the Kimera P-IV point-of-care plasmonic qPCR prototype for ultra rapid pathogen detection of <i>chlamydia trachomatis<\/i>"],"prefix":"10.1017","volume":"153","author":[{"given":"Joshua","family":"Hayes","sequence":"first","affiliation":[{"name":"Lady Davis Institute for Medical for Medical Research \u2013 Jewish General Hospital"},{"name":"McGill University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Soo","family":"Lee","sequence":"additional","affiliation":[{"name":"Lady Davis Institute for Medical for Medical Research \u2013 Jewish General Hospital"},{"name":"McGill University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Carnevale","sequence":"additional","affiliation":[{"name":"Concordia University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Shamir","sequence":"additional","affiliation":[{"name":"Nexless Healthcare LP"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Bohbot","sequence":"additional","affiliation":[{"name":"Nexless Healthcare LP"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew G.","family":"Kirk","sequence":"additional","affiliation":[{"name":"McGill University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1321-4414","authenticated-orcid":false,"given":"Miltiadis","family":"Paliouras","sequence":"additional","affiliation":[{"name":"McGill University"},{"name":"McGill University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Trifiro","sequence":"additional","affiliation":[{"name":"Lady Davis Institute for Medical for Medical Research \u2013 Jewish General Hospital"},{"name":"McGill University"},{"name":"McGill University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"key":"S0950268825000081_r30","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2023.1235837"},{"key":"S0950268825000081_r10","unstructured":"[10] Prevention, C.f.D.C.a. (2018) Combating the Threat of Antibiotic-Resistant Gonorrhea."},{"key":"S0950268825000081_r6","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.14.4.836-871.2001"},{"key":"S0950268825000081_r8","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/375681"},{"key":"S0950268825000081_r40","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-016-1320-7"},{"key":"S0950268825000081_r15","doi-asserted-by":"publisher","DOI":"10.1039\/D0AN02496A"},{"key":"S0950268825000081_r13","unstructured":"[13] Trifiro, M , Kirk, A and Paliouras, M (2017) Plasmonic PCR \u2013 The Next Generation in Point-of-Care Diagnostics. GenomeCanada, GenomeQu\u00e9bec. p. 59."},{"key":"S0950268825000081_r23","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2015.2712"},{"key":"S0950268825000081_r31","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.8544"},{"key":"S0950268825000081_r36","unstructured":"[36] Prevention, C.f.D.C.a. (2017) Antibiotic Resistance Threats in the United States."},{"key":"S0950268825000081_r12","unstructured":"[12] Chlamydia, gonorrhea and infectious syphilis in Canada: 2020 (infographic). 2020; Available from: https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/diseases-conditions\/chlamydia-gonorrhea-infectious-syphilis-canada-2020-infographic.html."},{"key":"S0950268825000081_r18","volume-title":"Nanoscience: Nanobiotechnology and Nanobiology","author":"Evrard","year":"2009"},{"key":"S0950268825000081_r38","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2013.0426"},{"key":"S0950268825000081_r29","doi-asserted-by":"publisher","DOI":"10.4161\/viru.26288"},{"key":"S0950268825000081_r44","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw217"},{"key":"S0950268825000081_r28","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.31.5.1060-1065.1993"},{"key":"S0950268825000081_r7","first-page":"3","article-title":"Tackling threats and future problems of multidrug-resistant bacteria","volume":"398","author":"Medina","year":"2016","journal-title":"Current Topics in Microbiology and Immunology"},{"key":"S0950268825000081_r14","doi-asserted-by":"publisher","DOI":"10.1038\/srep29836"},{"key":"S0950268825000081_r16","doi-asserted-by":"publisher","DOI":"10.1039\/C7AN00304H"},{"key":"S0950268825000081_r43","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2011.0358"},{"key":"S0950268825000081_r9","doi-asserted-by":"publisher","DOI":"10.4081\/idr.2017.6839"},{"key":"S0950268825000081_r19","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-4-263"},{"key":"S0950268825000081_r37","doi-asserted-by":"publisher","DOI":"10.1016\/j.suc.2012.01.015"},{"key":"S0950268825000081_r17","first-page":"S49","article-title":"Limit of blank, limit of detection and limit of quantitation","volume":"29","author":"Armbruster","year":"2008","journal-title":"Clinical Biochemist Reviews"},{"key":"S0950268825000081_r5","doi-asserted-by":"publisher","DOI":"10.1016\/S0377-1237(17)30450-1"},{"key":"S0950268825000081_r3","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.19.1.165-256.2006"},{"key":"S0950268825000081_r34","doi-asserted-by":"publisher","DOI":"10.1071\/SH12108"},{"key":"S0950268825000081_r32","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-020-01781-z"},{"key":"S0950268825000081_r27","doi-asserted-by":"publisher","DOI":"10.1007\/s00005-010-0076-z"},{"key":"S0950268825000081_r1","unstructured":"[1] WHO (2011) The Burden of Health Care-Associated Infection Worldwide."},{"key":"S0950268825000081_r35","unstructured":"[35] Canada, Go (2017) Tackling Antimicrobial Resistance and Antimicrobial Use: A Pan-Canadian Framework for Action."},{"key":"S0950268825000081_r22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bdq.2015.01.005"},{"key":"S0950268825000081_r41","unstructured":"[41] Organization WH (2017) Antibiotic-resistant gonorrhoea on the rise, new drugs needed."},{"key":"S0950268825000081_r39","unstructured":"[39] Tacconelli, E , et al. (2017) Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. The Lancet Infectious Diseases."},{"key":"S0950268825000081_r48","unstructured":"[48] Centre for Disease Control and Prevention (2017) Antibiotic Prescribing and Use in Hospitals and Long-Term care."},{"key":"S0950268825000081_r21","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14050477"},{"key":"S0950268825000081_r24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2672.2012.05384.x"},{"key":"S0950268825000081_r2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201609-1848OC"},{"key":"S0950268825000081_r33","doi-asserted-by":"publisher","DOI":"10.1093\/jaoacint\/qsaa045"},{"key":"S0950268825000081_r26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3000896"},{"key":"S0950268825000081_r46","unstructured":"[46] Canada, G.o. Antimicrobial Stewardship. 2016."},{"key":"S0950268825000081_r11","doi-asserted-by":"publisher","DOI":"10.1016\/j.talanta.2022.123409"},{"key":"S0950268825000081_r4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1198-743X.2004.00722.x"},{"key":"S0950268825000081_r42","doi-asserted-by":"publisher","DOI":"10.4137\/PMC.S14459"},{"key":"S0950268825000081_r47","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2753.2012.01840.x"},{"key":"S0950268825000081_r25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-93333-2"},{"key":"S0950268825000081_r20","volume-title":"Optimization of Reaactions to Reduce Formation of Primer Dimers","year":"2022"},{"key":"S0950268825000081_r45","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw118"}],"container-title":["Epidemiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0950268825000081","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T14:42:47Z","timestamp":1759848167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0950268825000081\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":48,"alternative-id":["S0950268825000081"],"URL":"https:\/\/doi.org\/10.1017\/s0950268825000081","relation":{},"ISSN":["0950-2688","1469-4409"],"issn-type":[{"value":"0950-2688","type":"print"},{"value":"1469-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"\u00a9 The Author(s), 2025. Published by Cambridge University Press","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http:\/\/creativecommons.org\/licenses\/by\/4.0), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"e27"}}